On the turnaround trail, tiny Corbus pays $7.5M for rival to Seagen's oncology ADC Padcev

On the turnaround trail, tiny Corbus pays $7.5M for rival to Seagen's oncology ADC Padcev

Source: 
Fierce Biotech
snippet: 

Corbus Pharmaceuticals is mounting a David vs. Goliath battle against Seagen, spending $7.5 million of its dwindling cash reserves on a challenger to the nectin-4 antibody-drug conjugate (ADC) Padcev.